Global Biologics Market MRFR Reveals Covid-19 Analysis for 2019-2027

Market Analysis

The global biologics market, during the forecast period, will register growth at a CAGR of 6.95%.The market for biologics is set to reach USD 285,520.4 million by 2023. As per market analysts, the global market is anticipated to witness growth owing to the factors such as development of several biopharmaceutical products as well as expansion of manufacturing capabilities. However, the biologics market will face challenges and restraints due to high biologics production costs and potential players delaying their plans during the forecast period.

Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1339

The adoption of novel biotechnology procedures in the biologics market is set to play a key role in determining the growth potential during the coming years. Analysts have also studied the market to understand potential threats and challenges the market companies could face. Although the market is poised to grow at a fast pace across product, disease indication, and manufacturing segments, factors such as restrictions in access to capacity could slow down the market's growth worldwide.

Market Segmentation

The Market Research Future report offers a complete segmental analysis of the biologics market based on manufacturing, disease indication, and product.

Based on product, the global biologics market is segmented into gene therapy, growth factors, vaccines, interleukins, monoclonal antibody, and others. Of these, the monoclonal antibody segment will have the largest share in the market during the forecast period for its increasing use for enhancing the body’s immunity system.

Based on disease indication, the biologics market is segmented into diabetes, cancer, psoriasis/psoriatic arthritis, rheumatoid arthritis, and others. Of these, the cancer segment dominated the market in 2018, but rheumatoid arthritis is predicted to dominate the biologics market over the forecast period for the rapid approval of different drugs by the regulatory agencies.

Based on manufacturing, the biologics market is segmented into outsourced and in-house. Of these, the outsourced segment will have the maximum share in the market during the forecast period for the presence of several pharmaceutical companies, especially in developing countries.

Regional Analysis

By region, the biologics market report covers the latest trends and growth opportunities across the Americas, the Asia Pacific, Europe, and the Middle East and Africa. Of these, the Americas will dominate the market during the forecast period. Various factors are propelling the growth of the biologics market in the region, such as investments in new facilities for producing drugs for clinical trials, strong economic growth of Canada and the US, and rapid adoption of manufacturing technologies. It is predicted to touch USD 129,652.7 million at a 4.31% CAGR.

The biologics market in the APAC region will grow at the fastest pace during the forecast period. Various factors are propelling the growth of the biologics market in the region, such as the changing healthcare sector, increasing geriatric populace, and the presence of different contract manufacturing organizations (CMOs) in the region. India is a major contributor in this region for its massive strides in biologics manufacturing.

Key Players

Notable players profiled in the biologics market report include GlaxoSmithKline Plc (UK), Eli Lilly and Company (US), Bayer AG (Germany), Sanofi (France), F. Hoffman-La Roche AG (Switzerland), Novartis AG (Switzerland), Amgen (US), Pfizer Inc. (US), AstraZeneca (UK), and AbbVie, Inc. (US). Key players have incorporated specific strategies to increase their market share, such as acquisitions, expansions, and new product launches.

Industry News

WuXi Biologics, a multinational organisation with leading open-access biologics networks and services, and Bayer recently announced that WuXi Biologics would take over and run Bayer's Drug Substance (DS) facility in Wuppertal. A long-term sublease deal and a relocation management contract are both planned by the firms. The total purchase value, including the sublease deal, is estimated to be about 150 million euros.

1 Report Prologue

2 Market Introduction

2.1 Introduction 15

2.2 Scope Of The Study 15

2.3 Assumptions & Limitations 15

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 19

3.3 Secondary Research 20

3.4 Market Size Estimation 21

3.5 Forecast Model 21

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 23

4.2.1 Increasing Healthcare Expenditure 23

4.2.2 Advancements In Biologics 24

4.2.3 Rising Prevalence Of Chronic And Acute Diseases 24

4.3 Restraints 24

4.3.1 Emergence Of Biosimilars 24

4.3.2 Adverse Effects Of Biologic Drugs 24

4.4 Opportunities 25

4.4.1 Strong Pipeline For Biologic Drugs 25

5 Market Factor Analysis

5.1 Value/Supply Chain Analysis 27

5.1.1 Research & Development 27

5.1.2 Raw Material 27

5.1.3 Manufacturer 27

5.1.4 Distributor 28

5.1.5 Customer 28

5.1.6 Consumer 28

5.2 Porter’s Five Force Analysis 29

5.2.1 Threat From A New Entrant 30

5.2.2 Bargaining Power Of Buyer 30

5.2.3 Bargaining Power Of Supplier 30

5.2.4 Threat From Substitute 31

5.2.5 Rivalry 31

5.3 Investment Opportunity Analysis 32

5.3.1 Investment Risks 32

5.3.2 Market Outlook 32

5.4 Pricing Analysis 32

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/biologics-market-1339